• New Science Ventures led Novadip’s € 10.4 million convertible financing round disclosed Sept. 21, 2026.
• Novadip is a late-stage regenerative medicine biotech developing cell-based therapies for bone repair.
• Proceeds fund completion of a pivotal Phase 3 trial for NVD003 in congenital pseudarthrosis of the tibia.
• Round lifts Novadip’s total convertible financing to € 20 million, including a prior € 9.6 million convertible loan.
• Financing unlocks the final tranche of an € 18 million EIB venture debt facility signed in 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Science Ventures LLC published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.